KR970706830A - 2, 2'-디티오-비스(에탄설포네이트)(디메스나)와 조합된 시스플라틴의 조성물(composition of cisplatin in combination with 2, 2＇-dithio-bis (ethanesulfonate) (dimesna) - Google Patents

2, 2'-디티오-비스(에탄설포네이트)(디메스나)와 조합된 시스플라틴의 조성물(composition of cisplatin in combination with 2, 2＇-dithio-bis (ethanesulfonate) (dimesna)

Info

Publication number
KR970706830A
KR970706830A KR1019970703171A KR19970703171A KR970706830A KR 970706830 A KR970706830 A KR 970706830A KR 1019970703171 A KR1019970703171 A KR 1019970703171A KR 19970703171 A KR19970703171 A KR 19970703171A KR 970706830 A KR970706830 A KR 970706830A
Authority
KR
South Korea
Prior art keywords
composition
cisplatin
dithio
ethanesulfonate
bis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019970703171A
Other languages
English (en)
Other versions
KR100411380B1 (ko
Inventor
허만 하우쉬어 프레드릭
하리다스 코차트
무라리 다나바란
가우라바람 레디 다샤라타
시타라무루 페다이아가리
Original Assignee
허만 하우쉬어 프레드릭
바이오누머릭 파마슈티칼스, 인코오포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 허만 하우쉬어 프레드릭, 바이오누머릭 파마슈티칼스, 인코오포레이티드 filed Critical 허만 하우쉬어 프레드릭
Publication of KR970706830A publication Critical patent/KR970706830A/ko
Application granted granted Critical
Publication of KR100411380B1 publication Critical patent/KR100411380B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

시스플라턴을 2,2'-디티오-비스(에탄설포네이트)의 약학적 허용 형태와 함께 투여하는 것은 시스플라틴의 신독성과 골수억제를 감소시키며 시스플라틴의 항암작용을 감소시킨다. 바람직하게는 시스플라틴과 설포네이트는 조성물, 특히 염소 이온과 나트륨 및 수소 양이온을 함유하는 살균된 주사가능한 용액으로 제제화된다.

Description

2,2'-디티오-비스(에탄설포네이트) (디메스나)와 조합된 시스플라틴의 조성물(COMPOSITION OF CISPLATIN IN COMBINATION WITH 2,2'-DITHIO-BIS (ETHANESULFONATE)(DIMESNA)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 시스플라틴과 2,2'-디티오-비스(에탄설포네이트)의 약학적 허용 형태를 포함하는, 암환자에게 투여하기에 적합한 조성물.
  2. 제1항에 있어서, pH 2 내지 6의 살균된 주사가능한 수용액 또는 현탁액 형태의 조성물.
  3. 제2항에 있어서, pH가 4 내지 6인 조성물.
  4. 제2항 또는 3항에 있어서, 추가로 완충용액을 포함하는 조성물.
  5. 제2,3,4항에 있어서, 염소 음이온과 나트륨 양이온 및 수소 양이온을 포함하는 조성물.
  6. 제5항에 있어서, 0.1 내지 1.0㎎/㎖의 시스플라틴, 1.0 내지 320㎎/㎖의 설포네이트, 10 내지 25㎎/㎖의 염화나트륨 및 정의된 pH를 제공하기 위한 염산 또는 인산을 포함하는 조성물.
  7. 제6항에 있어서, 추가로 10 내지 25㎎/㎖의 만니톨을 포함하는 조성물.
  8. 제1,2,3,4,5,6 또는 7항에 있어서, 동결건조물 형태의 조성물.
  9. 환자의 혈액에 시스플라틴과 설포네이트가 공존하도록 시스플라틴과 함께 거의 동시에 또는 순차적으로 환자에게 투여하기 위한 약제의 제조에서 2,2'-디티오-비스(에탄설포네이트)의 약학적 허용형태의 이용.
  10. 제9항에 있어서, 설포네이트의 수용액의 동결건조 형태의 이용.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970703171A 1994-11-14 1995-11-14 시스플라틴과2,2'-디티오-비스(에탄설포네이트)(디메스나)를포함하는조성물 Expired - Lifetime KR100411380B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/338,379 US5789000A (en) 1994-11-14 1994-11-14 Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US08/338,379 1994-11-14

Publications (2)

Publication Number Publication Date
KR970706830A true KR970706830A (ko) 1997-12-01
KR100411380B1 KR100411380B1 (ko) 2004-04-30

Family

ID=23324592

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970703171A Expired - Lifetime KR100411380B1 (ko) 1994-11-14 1995-11-14 시스플라틴과2,2'-디티오-비스(에탄설포네이트)(디메스나)를포함하는조성물

Country Status (13)

Country Link
US (5) US5789000A (ko)
EP (1) EP0792154B1 (ko)
JP (3) JP4171526B2 (ko)
KR (1) KR100411380B1 (ko)
CN (2) CN1165483B (ko)
AT (1) ATE237337T1 (ko)
AU (1) AU706181B2 (ko)
CA (1) CA2202170C (ko)
DE (1) DE69530412T2 (ko)
DK (1) DK0792154T3 (ko)
ES (1) ES2191717T3 (ko)
PT (1) PT792154E (ko)
WO (1) WO1996014852A1 (ko)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5919816A (en) * 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum
US6025488A (en) * 1994-11-14 2000-02-15 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6037336A (en) * 1996-09-23 2000-03-14 Bionumerik Pharmaceuticals, Inc. Reducing toxic effects of carboplatin using dithioethers
CN1129432C (zh) * 1996-09-23 2003-12-03 比奥纽默里克药物公司 采用二硫醚降低碳铂的毒性作用
US6312734B1 (en) * 1998-11-23 2001-11-06 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with cis-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
RU2144374C1 (ru) * 1998-11-23 2000-01-20 Закрытое акционерное общество "ВАМ" Способ получения композита окисленного глутатиона с cis-диаминодихлорплатиной и фармацевтических композиций на его основе, регулирующих метаболизм, пролиферацию, дифференцировку и механизмы апоптоза нормальных и трансформированных клеток
US20070142267A1 (en) * 1998-11-23 2007-06-21 Novelos Therapeutics, Inc. Methods for production of the oxidized glutathione composite with CIS-diamminedichloroplatinum and pharmaceutical compositions based thereof regulating metabolism, proliferation, differentiation and apoptotic mechanisms for normal and transformed cells
US6197831B1 (en) * 1999-02-09 2001-03-06 Bionumerik Pharmaceuticals, Inc. Method of treating septic shock
US6034126A (en) * 1999-05-24 2000-03-07 Bionumerik Pharmaceuticals, Inc. Method for treating glycol poisoning
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US6156350A (en) * 1999-12-02 2000-12-05 Corazon Technologies, Inc. Methods and kits for use in preventing restenosis
WO2001080832A2 (en) 2000-04-26 2001-11-01 Oregon Health Sciences University Administration of a thiol-based chemoprotectant compound
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
AU2877202A (en) * 2000-11-02 2002-05-15 Sloan Kettering Inst Cancer Methods for enhancing the efficacy of cytotoxic agents through the use of hsp90 inhibitors
US6540733B2 (en) * 2000-12-29 2003-04-01 Corazon Technologies, Inc. Proton generating catheters and methods for their use in enhancing fluid flow through a vascular site occupied by a calcified vascular occlusion
WO2002056755A2 (en) * 2001-01-19 2002-07-25 Bionumerik Pharmaceuticals, Inc. Method for treating cancer
CA2441228A1 (en) * 2001-03-23 2002-10-03 Aphton Corporation Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
KR20040049830A (ko) * 2001-07-09 2004-06-12 애프톤 코포레이션 간, 폐 및 식도의 암 및 전암 상태의 치료 및 예방
US6352979B1 (en) * 2001-08-20 2002-03-05 Lucinda Lizcano Method of treating snakebite and complications resulting therefrom
PL370867A1 (en) * 2001-09-24 2005-05-30 Tosk, Inc. Reduced toxicity cisplatin formulations and methods for using the same
US7176192B2 (en) * 2001-10-26 2007-02-13 Bionumerik Pharmaceuticals, Inc. Method for treating patients for radiation exposure
US6596320B1 (en) * 2002-01-11 2003-07-22 Bionumerik Pharmaceuticals, Inc. Method for treating cancer having greater efficacy and reduced adverse effects
CA2480045C (en) * 2002-03-28 2013-09-24 Medical College Of Ohio Method and compositions for the diagnosis and treatment of non-small cell lung cancer using gene expression profiles
US8710095B2 (en) * 2002-04-30 2014-04-29 Bionumerik Pharmaceuticals, Inc. Drugs for prophylaxis or mitigation of taxane-induced neurotoxicity
US20040014730A1 (en) * 2002-07-10 2004-01-22 Frederick Hausheer Formulations and methods of reducing toxicity of anti-infective agents
MXPA05006721A (es) * 2002-12-21 2005-09-30 Bionumerik Pharmaceuticals Inc Metodo para tratamiento de pacientes expuestos a agentes quimicos toxicos.
US7714139B2 (en) * 2003-03-27 2010-05-11 Lankenau Institute For Medcial Research IDO inhibitors and methods of use
JP4936898B2 (ja) * 2003-12-17 2012-05-23 バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド ジスルフィド類の合成方法
AU2005228897B2 (en) * 2004-03-29 2009-12-10 Cancer Advances, Inc. Monoclonal antibodies to gastrin hormone
US20090111735A1 (en) * 2004-05-12 2009-04-30 Bionumerik Pharmaceuticals, Inc. Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US20050256055A1 (en) * 2004-05-12 2005-11-17 Hausheer Frederick H Compounds and methods for reducing undesired toxicity of chemotherapeutic agents
US7235589B2 (en) 2004-09-21 2007-06-26 Bio Numerik Pharmaceuticals, Inc. Method of treating patients undergoing kidney dialysis
US20060063742A1 (en) * 2004-09-21 2006-03-23 Hausheer Frederick H Method of treatment for or protection against lymphedema
US7282602B2 (en) * 2004-09-21 2007-10-16 Bionumerik Pharmaceuticals, Inc. Medicinal disulfide salts
JP2008513536A (ja) 2004-09-22 2008-05-01 レセプター バイオロジックス インコーポレイテッド プロガストリンに対するモノクローナル抗体
CN100443081C (zh) * 2005-04-05 2008-12-17 吴一心 木犀草素与一种铂类化疗药物联合用于制备抗肿瘤的药物
AU2006320162B2 (en) * 2005-12-02 2013-07-25 The Johns Hopkins University Use of high-dose oxazaphosphorine drugs for treating immune disorders
DK1991237T3 (en) * 2005-12-13 2015-04-27 Bionumerik Pharmaceuticals Inc Chemoprotective methods and compositions
US20070219268A1 (en) * 2006-03-16 2007-09-20 Bionumerik Pharmaceuticals, Inc. Anti-cancer activity augmentation compounds and formulations and methods of use thereof
WO2008034071A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Method of identifying patients suitable for high-dose cyclophosphamide treatment
WO2008034074A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclosphosphamide in combination with anti-idiotypic vaccines
WO2008034076A2 (en) 2006-09-15 2008-03-20 The Johns Hopkins University Cyclophosphamide in combination with immune therapeutics
RU2009133447A (ru) * 2007-02-09 2011-03-20 Пониард Фармасьютикалз, Инк. (Us) Дозированная форма пикоплатина
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
JP2010533714A (ja) * 2007-07-16 2010-10-28 ポニアード ファーマシューティカルズ， インコーポレイテッド ピコプラチンのための経口製剤
WO2009039190A1 (en) * 2007-09-17 2009-03-26 Gene Express, Inc. Cancer risk biomarker
US9026372B2 (en) * 2007-11-21 2015-05-05 Accentia Biopharmaceuticals, Inc. Methods for providing a system of care for a high-dose oxazaphosphorine drug regimen
WO2009067690A2 (en) * 2007-11-21 2009-05-28 Accentia Biopharmaceuticals, Inc. Methods for safe and effective treatment using oxazaphosphorine drugs
AU2009210656A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Use of picoplatin and cetuximab to treat colorectal cancer
US9320760B2 (en) * 2008-03-14 2016-04-26 Bionumerik Pharmaceuticals, Inc. Compositions and methods of use of compounds to increase cancer patient survival time
CN102014891B (zh) 2008-03-14 2013-12-18 比奥纽默里克药物公司 增加癌症患者存活时间的化合物的组合物和使用方法
EP2252246B1 (en) * 2008-03-14 2014-06-18 Bionumerik Pharmaceuticals, Inc. Chemoprotective methods and compositions
EP2249825B1 (en) * 2008-03-14 2015-10-07 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
US20110064828A1 (en) * 2009-09-11 2011-03-17 Novelos Therapeutics, Incorporated Treatment of metastatic tumors and other conditions
TWI438009B (zh) * 2010-02-19 2014-05-21 Teikoku Pharma Usa Inc 紫杉烷前－乳劑調配物及其製造與使用之方法
SG185389A1 (en) 2010-05-03 2012-12-28 Teikoku Pharma Usa Inc Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
EP2804602B1 (en) * 2012-01-20 2024-12-04 Del Mar Pharmaceuticals Use of substituted hexitols including dianhydrogalactitol and analogs to treat neoplastic disease and cancer stem cells including glioblastoma multforme and medulloblastoma
MX2015000810A (es) * 2012-07-19 2015-06-05 Relypsa Inc Composiciones que comprenden polímeros reticulados con enlace a cationes.
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
JP7469225B2 (ja) 2017-06-15 2024-04-16 キャンサー アドヴァンシーズ インク． 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2806866C3 (de) * 1978-02-17 1981-02-12 Asta-Werke Ag Chemische Fabrik, 4800 Bielefeld Verwendung von Salzen von Dithiodialkansulfonsäuren
US4310515A (en) * 1978-05-30 1982-01-12 Bristol-Myers Company Pharmaceutical compositions of cisplatin
DE58900183D1 (de) * 1988-03-19 1991-08-29 Asta Pharma Ag Ifosfamid-mesna-lyophilisat und verfahren zu dessen herstellung.
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
JP3954115B2 (ja) * 1992-07-28 2007-08-08 アストラゼネカ・アクチエボラーグ 注射剤および注射剤キット
US5789000A (en) * 1994-11-14 1998-08-04 Bionumerik Pharmaceuticals, Inc. Sterile aqueous parenteral formulations of cis-diammine dichloro platinum

Also Published As

Publication number Publication date
CA2202170C (en) 2007-04-10
CA2202170A1 (en) 1996-05-23
US5866615A (en) 1999-02-02
US5866617A (en) 1999-02-02
WO1996014852A1 (en) 1996-05-23
KR100411380B1 (ko) 2004-04-30
CN101987111A (zh) 2011-03-23
CN1165483B (zh) 2012-09-05
AU706181B2 (en) 1999-06-10
MX9703460A (es) 1997-07-31
ATE237337T1 (de) 2003-05-15
DE69530412T2 (de) 2003-10-30
EP0792154A1 (en) 1997-09-03
ES2191717T3 (es) 2003-09-16
DE69530412D1 (de) 2003-05-22
PT792154E (pt) 2003-09-30
US5902610A (en) 1999-05-11
JP2012211198A (ja) 2012-11-01
JPH10509143A (ja) 1998-09-08
EP0792154B1 (en) 2003-04-16
AU4116896A (en) 1996-06-06
JP4171526B2 (ja) 2008-10-22
CN1165483A (zh) 1997-11-19
US5866169A (en) 1999-02-02
JP2008133304A (ja) 2008-06-12
DK0792154T3 (da) 2003-08-04
US5789000A (en) 1998-08-04

Similar Documents

Publication Publication Date Title
KR970706830A (ko) 2, 2'-디티오-비스(에탄설포네이트)(디메스나)와 조합된 시스플라틴의 조성물(composition of cisplatin in combination with 2, 2＇-dithio-bis (ethanesulfonate) (dimesna)
CO4700482A1 (es) Formulaciones de un analogo monomero de insulina
BR0214757A (pt) Formulações farmacêuticas de derivados de platina
CO5050325A1 (es) Composiciones que contienen acidos difosfonicos
NO875299L (no) Insulinpreparat for ikke-paranteral administrasjon.
KR900015737A (ko) 배합물
BR0109779A (pt) Soluções moleculares hidrofìlicas dispersas de carvedilol
BR0211801A (pt) Derivados de 7h-pirrolo[2,3-d]pirimidina
MX9203543A (es) Medicamento.
BR9912694A (pt) Composto para preparar medicamento de administração pulmonar
EP0214647A3 (en) Inclusion complexes of 7-isopropoxy-isoflavone and cyclodextrins, process for their preparation and pharmaceutical preparations containing these complexes
BR9508554A (pt) Preparação farmaceuticamente estável de oxaliplatina
DE69327432D1 (de) Heilmittel für wunden und hämorrhoiden
KR900701282A (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
KR970025615A (ko) 암 전이 억제제
HK93990A (en) Injectable ready-to-use solutions containing an antitumor anthracycline glycoside
MX9205568A (es) Composicion farmaceutica que contiene cantidades de 5-amino-1beta-d-ribofuranosil-imidazol-4-carboxamida.
KR950005325A (ko) 제약 조성물
BR0014233A (pt) Conjugados de 4-benzilaminoquinolina com ácido galênico e seus heteroanálogos, processos para a sua preparação, medicamentos contendo estes compostos e sua aplicação
ES478272A1 (es) Un procedimiento para la preparacion de una solucion acuosa esteril y estable de cisplatina.
RU96109524A (ru) Композиция - лекарственная форма противоартрозного средства глюкозамина гидрохлорида для иньекций
DK1019037T3 (da) Lægemiddel indeholdende delta-aminolevulinsyre
IT8322623A1 (it) Composizioni terapeutiche iniettabili contenenti sali stabili della s-adenosil-l-metionina
BR0314651A (pt) Composição farmacêutica, e, método para tratar infecção pelo hvi
BR9807444A (pt) Produto antimicrobial

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19970512

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20001027

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20021125

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20030722

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20021125

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20030822

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20030722

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20031031

Appeal identifier: 2003101003265

Request date: 20030822

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20030822

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20030822

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20030225

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20001027

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20031031

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20030922

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20031203

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20031204

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20061201

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20071129

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20081202

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20091124

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20101129

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20111124

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20121123

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20121123

Start annual number: 10

End annual number: 10

FPAY Annual fee payment

Payment date: 20131122

Year of fee payment: 11

PR1001 Payment of annual fee

Payment date: 20131122

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20141121

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20141121

Start annual number: 12

End annual number: 12

PC1801 Expiration of term